ENTA management strikes as being very shrewd and thorough in regards to cash deployment, they might not find a better opportunity then to use it here. I would have to imagine they are well aware of OCRX and its potential in the liver disease space but I do agree a deal is less likely simply because well deals in general are less likely :)
Market Data 
Markets 
AI
